Опыт использования инкретиномиметиков в лечении больных сахарным диабетом типа 2

1. Аметов А.С., Солуянова Т.Н. Современные подходы к комбинированному лечению сахарного диабета 2-го типа. Cons. Med. 2007; 9 (9): 16–23.
2. Анциферов М.Б., Дорофеева Л.Г. Инкретиномиметики в терапии сахарного диабета 2-го типа. Леч. врач 2009; 3: 12–7.
3. Викулова О.К., Шестакова М.В. Клиническая эффективность миметика инкретинов экзенатида: результаты исследований и показания к применению у больных сахарным диабетом типа 2. Cons. Med. 2008; 10 (9).
4. Abdul-Ghani MA, Defronzo RA. Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes. Diabetes Care 2009; 32 (2): 5194–8.
5. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systemic review and meta-analysis. JAMA 2007; 298): 194–206.
6. Apovian CM, Bergenstal RM, Cuddihy RV et al. Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes. Am J Med 2010; 123 (5): 9–17.
7. Barnett A, Ausworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007; 23: 1493–507.
8. Bunck MC, Diamant MD, Corner A, Elliasson B et al. One-Year Treatment With Exenatide Improves-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Diabetes Care 2009; 32 (5): 762–8.
9. Buse J, Henry R, Han J. Effests of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27 (11): 2628–35.
10. Christensen M, Knop FC. Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? Curr Diab Rep 2010; 10: 124–32.
11. Davis SN, Johns D, Maggs D. Exploring the substitution of exenatide for insulin in patients treated with insulin in combination with oral antidiabetes agents. Diabet Care 2007; 30: 2767–72.
12. DeFronzo R, Ratner R, Han J. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabet Care 2005; 28 (5): 1092–100.
13. Degn KB, Brock B, Juhl CB. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couter-regularion during hypoglycemia. Diabetes 2004; 53 (9): 2397–403.
14. Edwards CMB, Stanley SA, Davis R. Exendin-4 reduses fasting and postprandial glucose decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281 (1): E155–161.
15. Egоn JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87 (3): 1282–90.
16. Fehse FC, Trautmann ME, Hoist JJ, Halseth AE. Exenatide augments first- and second-phase insulin secretion in response to intravenous glu¬cose in subjects with type 2 diobetes. J Clin Endocrinol Metob 2005; 90: 5991–7.
17. Finemon MS, Bicsak ТА, Shen LZ. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diobetes. Diabetes Care 2003; 26 (8): 2370–7.
18. Heine RJ, Van Gaal LF, Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143 (8): 559–69.
19. Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004; 53: 5–13.
20. Improvement in Beta-Cell Function Observed After Three Years of BYETTAR (exenatide) Injection Therapy: Data Presented at ADA 2010. Study Showed Improvements Compared to Insulin Glargine. Copyright American Diabetes Association. Inc. June 26, 2010. Presentation p. 728.
21. Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28 (5): 1083–91.
22. Kim D, MacConell L, Zhuang D. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487–93.
23. Kolterman OG, Buse JB, Fineman MS. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–9.
24. Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448–60. 
25. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Rept 2003; 114: 189–96.
26. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301–7.
27. Nauck MA, Duran S, Kim D. A comparison of a twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259–67.
28. Nelson P, Poon T, Guan X et al. The incretinmimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes technology & therapeutics. 2007; 9: 317–26.
29. Poon T, Nelson P, Shen L. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7 (3): 467–77.
30. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH. Long term effects of exenatide therapy over 82 weeks on glycemic control ond weight in over-weigt mefformin-treored patients with type 2 diabetes mellitus. Diabetes Obes Metob 2006; 11: 233–8.
31. Shah P, Velio А, Rizza RA. Glucagon physiology, pathophysiology ond prospects of glucagons antagonists for the treatment of diabetes. Diabetes Monitor 2005; 17 (61): 3–10.
32. Vilsboll T, Krarup T, Madsbad S, Hoist JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111–9.
33. Wajchenberg BL. β-Cell failure in diabetes and preservation by clinical treatment. Endocrine Rev 2007; 28 (2): 187–218.
34. Xu G, Staffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270–6.
35. Zander M, Madsbad S, Madsen JL, Hoist JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-ceil function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824–30.
36. Zinman B, Hoogwerf BJ, Garcia SD. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477–85.

А.С.Аметов, Е.Н.Пакус